Home Interviews BioStock Studio: Expres2ion’s CEO gives status update

BioStock Studio: Expres2ion’s CEO gives status update

BioStock Studio: Expres2ion’s CEO gives status update

21 April, 2022

Biotech ExpreS2ion Biotechnologies – that develops vaccines for covid-19, breast cancer, influenza and malaria – is currently conducting a rights issue of 73 million SEK. CEO Bent U. Frandsen visited BioStock’s studio to give a status update on the covid-19 project, which is being developed together with Bavarian Nordic, and to tell us more about the rights issue.

Watch the interview with ExpreS2ion Biotechnologies CEO Bent U. Frandsen below.

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev